2234-943x

Frontiers in Oncology

Frontiers Media SA

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Attach ORCID iDs across 37272 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

High impact37272 DOIs
2

Add abstracts to 8200 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact8200 DOIs
3

Deposit reference lists for 1864 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact1864 DOIs

DOIs for this ISSN

Showing the top 5 of 10000 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Implications of the Hybrid Epithelial/Mesenchymal Phenotype… (10.3389/fonc.2015.00155)
Abstract References ORCID License
278.39 607
2 Radiation-induced brain injury: A review (10.3389/fonc.2012.00073)
Abstract References ORCID License
273.16 538
3 Trastuzumab: Updated Mechanisms of Action and Resistance in… (10.3389/fonc.2012.00062)
Abstract References ORCID License
262.84 424
4 Mitochondrial Dysfunction in Cancer (10.3389/fonc.2013.00292)
Abstract References ORCID License
258.88 387
5 Getting to Know Ovarian Cancer Ascites: Opportunities for Ta… (10.3389/fonc.2013.00256)
Abstract References ORCID License
256.47 366
6 The Keap1–Nrf2 system in cancers: stress response and anabol… (10.3389/fonc.2012.00200)
Abstract References ORCID License
251.32 325
7 Altered Tumor-Cell Glycosylation Promotes Metastasis (10.3389/fonc.2014.00028)
Abstract References ORCID License
248.43 304
8 Vascular Permeability and Drug Delivery in Cancers (10.3389/fonc.2013.00211)
Abstract References ORCID License
247.57 298
9 Oxidative Stress and Programmed Cell Death in Yeast (10.3389/fonc.2012.00064)
Abstract References ORCID License
240.48 253
10 Histone Ubiquitination and Deubiquitination in Transcription… (10.3389/fonc.2012.00026)
Abstract References ORCID License
239.27 246
11 Diffuse intrinsic pontine glioma: poised for progress (10.3389/fonc.2012.00205)
Abstract References ORCID License
238.92 244
12 Radiation as an immunological adjuvant: current evidence on… (10.3389/fonc.2012.00153)
Abstract References ORCID License
237.84 238
13 Targeting Nuclear Factor-Kappa B to Overcome Resistance to C… (10.3389/fonc.2013.00120)
Abstract References ORCID License
236.55 231
14 DNA Double-Strand Break Repair as Determinant of Cellular Ra… (10.3389/fonc.2013.00113)
Abstract References ORCID License
236.17 229
15 Complex Interplay between the P-Glycoprotein Multidrug Efflu… (10.3389/fonc.2014.00041)
Abstract References ORCID License
235.79 227
16 The convergence of radiation and immunogenic cell death sign… (10.3389/fonc.2012.00088)
Abstract References ORCID License
235.22 224
17 Beyond DNA Repair: Additional Functions of PARP-1 in Cancer (10.3389/fonc.2013.00290)
Abstract References ORCID License
233.24 214
18 Pyruvate dehydrogenase kinase as a novel therapeutic target… (10.3389/fonc.2013.00038)
Abstract References ORCID License
232.63 211
19 Targeting PI3K/Akt/mTOR Signaling in Cancer (10.3389/fonc.2014.00064)
Abstract ORCID License
232.45 1256
20 Radiation-induced effects and the immune system in cancer (10.3389/fonc.2012.00191)
Abstract References ORCID License
229.23 195
21 Tumor Targeting via Integrin Ligands (10.3389/fonc.2013.00222)
Abstract References ORCID License
229.23 195
22 The eEF1A Proteins: At the Crossroads of Oncogenesis, Apopto… (10.3389/fonc.2015.00075)
Abstract References ORCID License
227.65 188
23 Unmet support service needs and health-related quality of li… (10.3389/fonc.2013.00075)
Abstract References ORCID License
225.53 179
24 Tumor-Penetrating Peptides (10.3389/fonc.2013.00216)
Abstract References ORCID License
225.29 178
25 Computational and Experimental Models of Cancer Cell Respons… (10.3389/fonc.2013.00044)
Abstract References ORCID License
224.55 175
26 The Potential and Hurdles of Targeted Alpha Therapy – Clinic… (10.3389/fonc.2013.00324)
Abstract References ORCID License
222.79 168
27 HERV-K(HML-2), the Best Preserved Family of HERVs: Endogeniz… (10.3389/fonc.2013.00246)
Abstract References ORCID License
222.27 166
28 Cellular Potts Modeling of Tumor Growth, Tumor Invasion, and… (10.3389/fonc.2013.00087)
Abstract References ORCID License
221.48 163
29 Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Resea… (10.3389/fonc.2013.00183)
Abstract References ORCID License
221.48 163
30 Glycogen Synthesis is Induced in Hypoxia by the Hypoxia-Indu… (10.3389/fonc.2012.00018)
Abstract References ORCID License
221.22 162
31 Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hyp… (10.3389/fonc.2012.00089)
Abstract References ORCID License
220.68 160
32 The emerging role of fumarate as an oncometabolite (10.3389/fonc.2012.00085)
Abstract References ORCID License
220.41 159
33 The interplay between autophagy and ROS in tumorigenesis (10.3389/fonc.2012.00171)
Abstract References ORCID License
220.14 158
34 The Notch ligand Jagged1 as a target for anti-tumor therapy (10.3389/fonc.2014.00254)
Abstract References ORCID License
219.87 157
35 Current Evidence Linking Polyunsaturated Fatty Acids with Ca… (10.3389/fonc.2013.00224)
Abstract References ORCID License
219.31 155
36 Dying cell clearance and its impact on the outcome of tumor… (10.3389/fonc.2012.00116)
Abstract References ORCID License
218.75 153
37 Immune Infiltration and Prostate Cancer (10.3389/fonc.2015.00128)
Abstract References ORCID License
218.75 153
38 Atypical Teratoid Rhabdoid Tumor: Current Therapy and Future… (10.3389/fonc.2012.00114)
Abstract References ORCID License
217.03 147
39 Differential Roles of PML Isoforms (10.3389/fonc.2013.00125)
Abstract References ORCID License
216.73 146
40 The Genomic and Proteomic Content of Cancer Cell-Derived Exo… (10.3389/fonc.2012.00038)
Abstract References ORCID License
216.44 145
41 Strategies to Increase Drug Penetration in Solid Tumors (10.3389/fonc.2013.00193)
Abstract References ORCID License
216.44 145
42 Peptide Hydrogels – Versatile Matrices for 3D Cell Culture i… (10.3389/fonc.2015.00092)
Abstract References ORCID License
216.14 144
43 Pediatric High Grade Glioma: a Review and Update on Tumor Cl… (10.3389/fonc.2012.00105)
Abstract References ORCID License
215.84 143
44 The Human Cathelicidin Antimicrobial Peptide LL-37 and Mimic… (10.3389/fonc.2015.00144)
Abstract References ORCID License
215.84 143
45 Immunosuppressive Mechanisms of Malignant Gliomas: Parallels… (10.3389/fonc.2015.00153)
Abstract References ORCID License
215.84 143
46 The Proline Regulatory Axis and Cancer (10.3389/fonc.2012.00060)
Abstract References ORCID License
214.30 138
47 Structural Implications for Selective Targeting of PARPs (10.3389/fonc.2013.00301)
Abstract References ORCID License
213.99 137
48 VDAC1: from structure to cancer therapy (10.3389/fonc.2012.00164)
Abstract References ORCID License
213.35 135
49 Ways to Enhance Lymphocyte Trafficking into Tumors and Fitne… (10.3389/fonc.2013.00231)
Abstract References ORCID License
213.35 135
50 Radiation, Inflammation, and Immune Responses in Cancer (10.3389/fonc.2012.00058)
Abstract References ORCID License
211.39 129